The facts

  1. LiGeR-HN1 (NCT06525220) is a global, randomized, open-label study comparing the combination with pembrolizumab alone as first-line treatment for recurrent or metastatic PD-L1-positive head-and-neck squamous-cell carcinoma. [1][2]

  2. Genmab reports an overall-survival hazard ratio of 0.50 (95% confidence interval 0.37–0.67; p<0.0001) at the first interim analysis. This measures relative death hazard, not an absolute 50-percentage-point survival improvement. [1][3]

  3. The reported objective-response odds ratio is 3.17 (95% confidence interval 2.06–4.89; p<0.0001). An odds ratio is not the absolute response rate. [1]

  4. The sponsor-submitted registry lists 699 actual enrolled participants, last updated on 25 September. That is not a verified denominator for the interim efficacy analysis; the registry contains no posted results. [2]

  5. Genmab reports no new safety signals but has not supplied detailed adverse-event rates in the checked announcement. Petosemtamab targets EGFR and LGR5; the company says its safety and efficacy are not established. [1]

Still unconfirmed

  • Interim analysis denominators and follow-up, absolute response and median-survival results, detailed safety data, full peer-reviewed findings and regulatory outcomes.

Sources

References support the numbered facts above. Source checks: 30 Oct 2026, 11:31 UTC.

  1. LiGeR-HN1 interim Phase 3 results announcement

    Genmab · Primary source · 28 Oct 2026

    Native 403 resolved through actual web source, including trial methods, statistics and investigational-status sections. No complete peer-reviewed Phase 3 dataset was furnished. Company-described independent monitoring is not separate outcome replication.

  2. LiGeR-HN1 study record NCT06525220

    ClinicalTrials.gov / Merus B.V. · Primary source · 29 Jul 2024

    Actual official API record read at https://clinicaltrials.gov/api/v2/studies/NCT06525220. Last posted update 25 September 2026; enrollment is actual 699, results absent. Sponsor-submitted registry information is not independent outcome validation.

  3. Reporting on Genmab's Phase 3 bispecific combination results

    Fierce Biotech / Michael Gibney · Reporting · 28 Oct 2026

    Actual report read via web fallback after native 403. Questex's newsroom is separate from Genmab; it reports the company's topline results. Earlier Phase 2 response/median-survival figures are not mixed with Phase 3.

Report a factual error